A trial looking at lenalidomide after chemotherapy for T cell lymphoma of the skin
Cancer type:
Status:
Phase:
This trial was looking at lenalidomide after treatment with chemotherapy for advanced T cell lymphoma of the skin.
T cell lymphomas of the skin (CTCL) are types of non Hodgkin lymphoma. Mycosis fungoides and Sezary syndrome are the most common types of T cell skin lymphomas, although they are still rare.
Doctors usually treat advanced T cell lymphoma of the skin with chemotherapy drugs called gemcitabine or liposomal doxorubicin. You may also have radiotherapy.
Chemotherapy often shrinks or gets rid of the cancer but sadly it can start to grow again. Doctors are looking for treatments to help people in this situation. In this trial they were testing a drug called lenalidomide.
Lenalidomide is a type of biological therapy. It works mainly by helping the body’s 
target cancer cells.
Doctors wanted to find out
- If having lenalidomide after chemotherapy could prevent or delay the cancer coming back
- More about the side effects
Summary of results
We have contacted the trial team who tell us that unfortunately they don’t expect to be making results available for this trial.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Sean Whittaker
Supported by
European Organisation for Research and Treatment of Cancer (EORTC)
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
